A K Wallin1, K Blennow, N Andreasen, L Minthon. 1. Department of Psychiatry, Neuropsychiatric Clinic, Malmö University Hospital, Malmö, Sweden. asa.k.wallin@skane.se
Abstract
UNLABELLED: Cerebrospinal fluid (CSF) samples from 21 patients with a clinical diagnosis of Alzheimer's disease (AD) participating in a 5-year treatment study with the choline esterase inhibitor tacrin were retrospectively analyzed for the contents of beta-amyloid (Abeta42), total tau (T-tau) and phosphorylated tau (P-tau). A significant positive correlation between the level of P-tau and the number of symptoms according to the DSM-IV criteria (p = 0.041) and the NINCDS-ADRDA (p = 0.029) was observed (i.e. higher levels were found in cases with more symptoms). A significant positive correlation between T-tau, P-tau and ADAS-cog score was identified (i.e. higher levels were found with more severe cognitive dysfunction). Patients who died during the 5-year follow-up had significantly lower levels of Abeta42 (p = 0.011) than those who were still alive. Patients who had died in a 6-year follow-up had significantly lower levels of Abeta42 (p = 0.034) and higher levels of T-tau (p = 0.041) than patients still alive. CONCLUSION: CSF biomarkers do aid the clinical diagnosis of AD. Increased levels of P-tau and T-tau are possible markers for severity and abundance of symptoms in AD. Low levels of Abeta42 may indicate a higher risk of early death in AD.
UNLABELLED: Cerebrospinal fluid (CSF) samples from 21 patients with a clinical diagnosis of Alzheimer's disease (AD) participating in a 5-year treatment study with the choline esterase inhibitor tacrin were retrospectively analyzed for the contents of beta-amyloid (Abeta42), total tau (T-tau) and phosphorylated tau (P-tau). A significant positive correlation between the level of P-tau and the number of symptoms according to the DSM-IV criteria (p = 0.041) and the NINCDS-ADRDA (p = 0.029) was observed (i.e. higher levels were found in cases with more symptoms). A significant positive correlation between T-tau, P-tau and ADAS-cog score was identified (i.e. higher levels were found with more severe cognitive dysfunction). Patients who died during the 5-year follow-up had significantly lower levels of Abeta42 (p = 0.011) than those who were still alive. Patients who had died in a 6-year follow-up had significantly lower levels of Abeta42 (p = 0.034) and higher levels of T-tau (p = 0.041) than patients still alive. CONCLUSION: CSF biomarkers do aid the clinical diagnosis of AD. Increased levels of P-tau and T-tau are possible markers for severity and abundance of symptoms in AD. Low levels of Abeta42 may indicate a higher risk of early death in AD.
Authors: Liana G Apostolova; Kristy S Hwang; John P Andrawis; Amity E Green; Sona Babakchanian; Jonathan H Morra; Jeffrey L Cummings; Arthur W Toga; John Q Trojanowski; Leslie M Shaw; Clifford R Jack; Ronald C Petersen; Paul S Aisen; William J Jagust; Robert A Koeppe; Chester A Mathis; Michael W Weiner; Paul M Thompson Journal: Neurobiol Aging Date: 2010-06-11 Impact factor: 4.673
Authors: Charles B Malpas; Michael M Saling; Dennis Velakoulis; Patricia Desmond; Terence J O'Brien Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Seong Jae Hwang; Maxwell D Collins; Sathya N Ravi; Vamsi K Ithapu; Nagesh Adluru; Sterling C Johnson; Vikas Singh Journal: Proc IEEE Int Conf Comput Vis Date: 2015-12
Authors: George S Vlachos; George P Paraskevas; Dimitris Naoumis; Elizabeth Kapaki Journal: J Neural Transm (Vienna) Date: 2012-03-30 Impact factor: 3.575
Authors: Evelin L Schaeffer; Vanessa J De-Paula; Emanuelle R da Silva; Barbara de A Novaes; Heni D Skaf; Orestes V Forlenza; Wagner F Gattaz Journal: J Neural Transm (Vienna) Date: 2011-03-09 Impact factor: 3.575
Authors: Anders M Fjell; Kristine B Walhovd; Christine Fennema-Notestine; Linda K McEvoy; Donald J Hagler; Dominic Holland; Kaj Blennow; James B Brewer; Anders M Dale Journal: Cereb Cortex Date: 2010-01-04 Impact factor: 5.357